 | • レポートコード：GIR-107A11987 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、81ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、血管運動症状更年期治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。血管運動症状更年期治療の種類別市場規模（エステトロール、フェゾリネタント、FP-101、HBN-2、その他）、用途別市場規模（病院、在宅ケア、クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・血管運動症状更年期治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amgen Inc.、EndoCeutics, Inc.、Euroscreen S.A.、MenoGeniX, Inc.、Mithra Pharmaceuticals S.A.、Pherin Pharmaceuticals, Inc.、Pivot Pharmaceuticals Inc、Radius Health, Inc.、TherapeuticsMD, Inc. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：エステトロール、フェゾリネタント、FP-101、HBN-2、その他 ・用途別分析2016年-2026年：病院、在宅ケア、クリニック ・血管運動症状更年期治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・血管運動症状更年期治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・血管運動症状更年期治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・血管運動症状更年期治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・血管運動症状更年期治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Vasomotor Symptoms of Menopause Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Vasomotor Symptoms of Menopause Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Vasomotor Symptoms of Menopause Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Vasomotor Symptoms of Menopause Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Estetrol
Fezolinetant
FP-101
HBN-2
Others
Market segment by Application, can be divided into
Hospital
Homecare
Clinic
Market segment by players, this report covers
Amgen Inc.
EndoCeutics, Inc.
Euroscreen S.A.
MenoGeniX, Inc.
Mithra Pharmaceuticals S.A.
Pherin Pharmaceuticals, Inc.
Pivot Pharmaceuticals Inc
Radius Health, Inc.
TherapeuticsMD, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Vasomotor Symptoms of Menopause Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Vasomotor Symptoms of Menopause Treatment, with revenue, gross margin and global market share of Vasomotor Symptoms of Menopause Treatment from 2019 to 2021.
Chapter 3, the Vasomotor Symptoms of Menopause Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Vasomotor Symptoms of Menopause Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Vasomotor Symptoms of Menopause Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Vasomotor Symptoms of Menopause Treatment
1.2 Classification of Vasomotor Symptoms of Menopause Treatment by Type
1.2.1 Overview: Global Vasomotor Symptoms of Menopause Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type in 2020
1.2.3 Estetrol
1.2.4 Fezolinetant
1.2.5 FP-101
1.2.6 HBN-2
1.2.7 Others
1.3 Global Vasomotor Symptoms of Menopause Treatment Market by Application
1.3.1 Overview: Global Vasomotor Symptoms of Menopause Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Homecare
1.3.4 Clinic
1.4 Global Vasomotor Symptoms of Menopause Treatment Market Size & Forecast
1.5 Global Vasomotor Symptoms of Menopause Treatment Market Size and Forecast by Region
1.5.1 Global Vasomotor Symptoms of Menopause Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Vasomotor Symptoms of Menopause Treatment Market Size by Region, (2016-2021)
1.5.3 North America Vasomotor Symptoms of Menopause Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Vasomotor Symptoms of Menopause Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Vasomotor Symptoms of Menopause Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Vasomotor Symptoms of Menopause Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Vasomotor Symptoms of Menopause Treatment Market Drivers
1.6.2 Vasomotor Symptoms of Menopause Treatment Market Restraints
1.6.3 Vasomotor Symptoms of Menopause Treatment Trends Analysis
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Amgen Inc. Details
2.1.2 Amgen Inc. Major Business
2.1.3 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.1.4 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Amgen Inc. Recent Developments and Future Plans
2.2 EndoCeutics, Inc.
2.2.1 EndoCeutics, Inc. Details
2.2.2 EndoCeutics, Inc. Major Business
2.2.3 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.2.4 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 EndoCeutics, Inc. Recent Developments and Future Plans
2.3 Euroscreen S.A.
2.3.1 Euroscreen S.A. Details
2.3.2 Euroscreen S.A. Major Business
2.3.3 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.3.4 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Euroscreen S.A. Recent Developments and Future Plans
2.4 MenoGeniX, Inc.
2.4.1 MenoGeniX, Inc. Details
2.4.2 MenoGeniX, Inc. Major Business
2.4.3 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.4.4 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 MenoGeniX, Inc. Recent Developments and Future Plans
2.5 Mithra Pharmaceuticals S.A.
2.5.1 Mithra Pharmaceuticals S.A. Details
2.5.2 Mithra Pharmaceuticals S.A. Major Business
2.5.3 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.5.4 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Mithra Pharmaceuticals S.A. Recent Developments and Future Plans
2.6 Pherin Pharmaceuticals, Inc.
2.6.1 Pherin Pharmaceuticals, Inc. Details
2.6.2 Pherin Pharmaceuticals, Inc. Major Business
2.6.3 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.6.4 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Pherin Pharmaceuticals, Inc. Recent Developments and Future Plans
2.7 Pivot Pharmaceuticals Inc
2.7.1 Pivot Pharmaceuticals Inc Details
2.7.2 Pivot Pharmaceuticals Inc Major Business
2.7.3 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.7.4 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pivot Pharmaceuticals Inc Recent Developments and Future Plans
2.8 Radius Health, Inc.
2.8.1 Radius Health, Inc. Details
2.8.2 Radius Health, Inc. Major Business
2.8.3 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.8.4 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Radius Health, Inc. Recent Developments and Future Plans
2.9 TherapeuticsMD, Inc.
2.9.1 TherapeuticsMD, Inc. Details
2.9.2 TherapeuticsMD, Inc. Major Business
2.9.3 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
2.9.4 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 TherapeuticsMD, Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Vasomotor Symptoms of Menopause Treatment Players Market Share
3.2.2 Top 10 Vasomotor Symptoms of Menopause Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Vasomotor Symptoms of Menopause Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application (2016-2021)
5.2 Vasomotor Symptoms of Menopause Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2026)
6.2 North America Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2026)
6.3 North America Vasomotor Symptoms of Menopause Treatment Market Size by Country
6.3.1 North America Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2026)
6.3.2 United States Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2026)
7.2 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2026)
7.3 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country
7.3.1 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2026)
7.3.2 Germany Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
7.3.3 France Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Region
8.3.1 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Region (2016-2026)
8.3.2 China Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
8.3.5 India Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2026)
9.2 South America Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2026)
9.3 South America Vasomotor Symptoms of Menopause Treatment Market Size by Country
9.3.1 South America Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country
10.3.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Vasomotor Symptoms of Menopause Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Vasomotor Symptoms of Menopause Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Vasomotor Symptoms of Menopause Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Region (2021-2026)
Table 6. Amgen Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Inc. Major Business
Table 8. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 9. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. EndoCeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 11. EndoCeutics, Inc. Major Business
Table 12. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 13. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Euroscreen S.A. Corporate Information, Head Office, and Major Competitors
Table 15. Euroscreen S.A. Major Business
Table 16. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 17. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. MenoGeniX, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. MenoGeniX, Inc. Major Business
Table 20. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 21. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Mithra Pharmaceuticals S.A. Corporate Information, Head Office, and Major Competitors
Table 23. Mithra Pharmaceuticals S.A. Major Business
Table 24. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 25. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Pherin Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Pherin Pharmaceuticals, Inc. Major Business
Table 28. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 29. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Pivot Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 31. Pivot Pharmaceuticals Inc Major Business
Table 32. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 33. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Radius Health, Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Radius Health, Inc. Major Business
Table 36. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 37. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. TherapeuticsMD, Inc. Corporate Information, Head Office, and Major Competitors
Table 39. TherapeuticsMD, Inc. Major Business
Table 40. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 41. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) by Players (2019-2021)
Table 43. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Players (2019-2021)
Table 44. Breakdown of Vasomotor Symptoms of Menopause Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Vasomotor Symptoms of Menopause Treatment Players Head Office, Products and Services Provided
Table 46. Vasomotor Symptoms of Menopause Treatment Mergers & Acquisitions in the Past Five Years
Table 47. Vasomotor Symptoms of Menopause Treatment New Entrants and Expansion Plans
Table 48. Global Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) by Type (2016-2021)
Table 49. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Type (2016-2021)
Table 50. Global Vasomotor Symptoms of Menopause Treatment Revenue Forecast by Type (2021-2026)
Table 51. Global Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2021)
Table 52. Global Vasomotor Symptoms of Menopause Treatment Revenue Forecast by Application (2021-2026)
Table 53. North America Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Vasomotor Symptoms of Menopause Treatment Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Vasomotor Symptoms of Menopause Treatment Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Vasomotor Symptoms of Menopause Treatment Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Vasomotor Symptoms of Menopause Treatment Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Vasomotor Symptoms of Menopause Treatment Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Vasomotor Symptoms of Menopause Treatment Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Vasomotor Symptoms of Menopause Treatment Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Vasomotor Symptoms of Menopause Treatment Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Vasomotor Symptoms of Menopause Treatment Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Vasomotor Symptoms of Menopause Treatment Picture
Figure 2. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type in 2020
Figure 3. Estetrol
Figure 4. Fezolinetant
Figure 5. FP-101
Figure 6. HBN-2
Figure 7. Others
Figure 8. Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application in 2020
Figure 9. Hospital Picture
Figure 10. Homecare Picture
Figure 11. Clinic Picture
Figure 12. Global Vasomotor Symptoms of Menopause Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Vasomotor Symptoms of Menopause Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Region in 2020
Figure 16. North America Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Vasomotor Symptoms of Menopause Treatment Market Drivers
Figure 22. Vasomotor Symptoms of Menopause Treatment Market Restraints
Figure 23. Vasomotor Symptoms of Menopause Treatment Market Trends
Figure 24. Amgen Inc. Recent Developments and Future Plans
Figure 25. EndoCeutics, Inc. Recent Developments and Future Plans
Figure 26. Euroscreen S.A. Recent Developments and Future Plans
Figure 27. MenoGeniX, Inc. Recent Developments and Future Plans
Figure 28. Mithra Pharmaceuticals S.A. Recent Developments and Future Plans
Figure 29. Pherin Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 30. Pivot Pharmaceuticals Inc Recent Developments and Future Plans
Figure 31. Radius Health, Inc. Recent Developments and Future Plans
Figure 32. TherapeuticsMD, Inc. Recent Developments and Future Plans
Figure 33. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Players in 2020
Figure 34. Vasomotor Symptoms of Menopause Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Vasomotor Symptoms of Menopause Treatment Revenue Market Share in 2020
Figure 36. Global Top 10 Players Vasomotor Symptoms of Menopause Treatment Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Type in 2020
Figure 39. Global Vasomotor Symptoms of Menopause Treatment Market Share Forecast by Type (2021-2026)
Figure 40. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Application in 2020
Figure 41. Global Vasomotor Symptoms of Menopause Treatment Market Share Forecast by Application (2021-2026)
Figure 42. North America Vasomotor Symptoms of Menopause Treatment Sales Market Share by Type (2016-2026)
Figure 43. North America Vasomotor Symptoms of Menopause Treatment Sales Market Share by Application (2016-2026)
Figure 44. North America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Country (2016-2026)
Figure 45. United States Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Vasomotor Symptoms of Menopause Treatment Sales Market Share by Type (2016-2026)
Figure 49. Europe Vasomotor Symptoms of Menopause Treatment Sales Market Share by Application (2016-2026)
Figure 50. Europe Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Country (2016-2026)
Figure 51. Germany Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Region (2016-2026)
Figure 59. China Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Vasomotor Symptoms of Menopause Treatment Sales Market Share by Type (2016-2026)
Figure 66. South America Vasomotor Symptoms of Menopause Treatment Sales Market Share by Application (2016-2026)
Figure 67. South America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
世界の更年期ウェルネス市場 2021：企業別、地域別、種類・用途別 The Menopause Wellness market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations,…- 世界の軟骨無形成症治療市場 2021：企業別、地域別、種類・用途別 The Achondroplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の髄膜炎菌感染症治療市場 2021：企業別、地域別、種類・用途別 The Meningococcal Infections Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
- 世界の総胆管結石症治療市場 2021：企業別、地域別、種類・用途別 The Choledocholithiasis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界の黄熱病治療市場 2021：企業別、地域別、種類・用途別 The Yellow Fever Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulati…